Login / Signup

Improved Outcome for ALL by Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for Other Risk Groups.

Rob PietersHester de Groot-KrusemanMarta FioccoFemke VerwerMerian Van OverveldEdwin SonneveldVincent H J van der VeldenH Berna BeverlooMarc BieringsNatasja DorsValerie de HaasPeter M HoogerbruggeInge M Van der SluisWim TissingMargreet A VeeningJudith M BoerMonique Den Boer
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
, DS, and PPR ALL. It has to be noted that these results were obtained in a nonrandomized study using a historical control group.
Keyphrases
  • acute lymphoblastic leukemia